Australian Clinical Trials Alliance

2025 ACTA Awards

Nomination guidelines and eligibility criteria

ACTA Trial of The Year Award

Trials nominated for the ***ACTA Trial of the Year Award*** must have been collaboratively developed, multi-centre, investigator-led, randomised controlled trials designed to improve patient outcomes or healthcare delivery. The trial must have been designed and led by a network or investigator group that is a current Full or Associate Member of ACTA and the **primary results**[1] of the trial must have been published in 2024. The trial must not have previously received an Award or have been a runner-up.

A peer review panel of senior trialists appointed by the **ACTA Board**[2] will review all nominations and judge the trial that is the best demonstration of the following standards:

- It addressed a critical gap in the evidence or a significant innovation in healthcare delivery
- The quality of the research design, conduct and analysis were outstanding
- There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or healthcare delivery

Prize

The Chief Investigator of the trial receiving the ***ACTA Trial of the Year Award*** will receive $2,500 to benefit their group and enhance the future of healthcare through the attendance at a conference, symposium or training course. An outline of how the funds will be expended is required.

ACTA Awards ceremony and ACTA Symposium

The Chief Investigator (or a nominated senior investigator) will be awarded a complimentary ticket to attend and accept the award at the ***ACTA Awards*** on May 20, 2025 and one complimentary registration and an invitation to give a presentation at the ***2025 ACTA Symposium*** (date to be

[1] The first publication reporting the analysis of trial's primary endpoint as specified in the online trial registration profile. The published results of a different domain of a *previously awarded* platform trial is not eligible.
[2] The ACTA Board will consider the recommendations of the judging panels in making decisions to announce the winning trials. The ACTA Board's decision will be final.

advised) on key lessons learned from the trial. Participation in media coverage surrounding the event is expected. Return economy airfares will be provided.

Australian Clinical Trials Alliance

ACTA-STInG Excellence in Trial Statistics Award

Trials nominated for the ***ACTA-STInG Excellence in Trial Statistics Award*** must have been designed and led by a network or investigator group that is a current Full or Associate Member of ACTA and the **primary results**[1] of the trial must have been published (online or in print) in 2024. The trial must not have previously received an Award or have been a runner-up.

An expert panel of statisticians convened by *ACTA-STInG* will consider the statistical methods summary provided along with the trial's published statistical analysis plan and primary results paper and judge the trial that is the best demonstration of the following standards:

- The statistical aspects of trial design and planning (sample size, randomisation, analytical methods) were of high quality, appropriate for the research question(s), and documented in a publicly accessible statistical analysis plan following good statistical procedures/practice
- The statistical analyses were executed as planned and, where not, deviations were transparent, of high quality, and executed well following good statistical procedures/practice
- The reporting and interpretation of the statistical aspects of the trial were appropriate, transparent, and supported by results from pre-specified analyses and/or well-defended departures from planned procedures following good statistical procedures/practice.

Prize

The Chief Statistician of the trial receiving the ***ACTA-STInG Excellence in Trial Statistics Award*** will receive $1,000 to benefit their group and build capacity and capability within the sector through the attendance at a conference, symposium or training course. An outline of how the funds will be expended is required.

ACTA Awards ceremony and ACTA Symposium

The Chief Statistician (or a nominated senior Statistician of the trial, network or investigator group) will be awarded one complimentary ticket to attend and accept the award at the ***ACTA Awards*** on May 20, 2025 and one complimentary registration and an invitation to give a presentation at the ***2025 ACTA Symposium*** (date to be advised) on key lessons learned from the trial. Participation in media coverage surrounding the event is expected. Return economy airfares will be provided.

ACTA Consumer Involvement Award

Trials nominated for the ***ACTA Consumer Involvement Award*** must demonstrate exceptional creative and collaborative initiatives that involved consumers, incorporating the needs and values of patients and the public into priority setting, trial protocol development and design. The trial must have been designed and led by a network or investigator group that is a current Full or Associate Member of ACTA. The trial must not have previously received an Award or have been a runner-up. For this Award, publication of the trial in the year 2024 is *not required*.

A peer-led panel of senior trialists and consumer representatives appointed by the ACTA Board will review all nominations and judge the trial that is the best demonstration of the following standards:

- Consumers were significantly involved in protocol development or design activities

- Consumer involvement provided valuable and exceptional guidance to the proposed conduct of the trial.

Prize

The Chief Investigator of the trial awarded the ***ACTA Consumer Involvement Award*** will receive $1,000 to benefit their group and enhance the future of consumer involvement in healthcare through the attendance at a conference, registry or training course. An outline of how the funds will be expended is required.

ACTA Awards ceremony and ACTA Symposium

The Consumer Representative (or a nominated senior member of the investigator group) will be awarded one complimentary ticket to attend and accept the award at the ***ACTA Awards*** on May 20, 2025 and one complimentary registration and an invitation to give a presentation at the ***2025 ACTA Symposium*** (date to be advised) on key lessons learned from the trial. Participation in media coverage surrounding the event is expected. Return economy airfares will be provided.

ACTA-HEAT Excellence in Trial-Based Health Economics Award

Trials nominated for the ***ACTA-HEAT Excellence in Trial-Based Health Economics Award*** will be reviewed by an expert panel of health economists convened by *ACTA-HEAT*. The trial must have been designed and led by a network or investigator group that is a current Full or Associate Member of ACTA and the economic analysis of the trial must have been published (online or in print) in 2024. The trial must not have previously received an Award or have been a runner-up.

This panel will consider the health economics methods summary provided within the trial nomination form, along with the trial's health economics analysis plan; health economics results paper and/or primary results paper and judge the trial that is the best demonstration of the following standards:

- The health economics aspects of trial design and planning (e.g. collection and valuation of healthcare use data, patient-reported outcomes) were of high quality, and appropriate for the research question(s)
- The health economics analyses were executed as planned (e.g. as stated in the Health Economics Analysis Plan (HEAP) and, where not, deviations were transparent, of high quality, and well executed following best practices
- The reporting and interpretation of the health economic analyses and sensitivity analyses were appropriate, transparent, and supported by results
- The health economics analyses make a significant contribution to trials methodology, or health and social policy, or health impact.

Prize

The Lead Health Economist awarded the ***ACTA-HEAT Excellence in Trial-Based Health Economics Award*** will receive $1,000 to build capacity and capability within the sector through the attendance at a conference, symposium or health economics training course. An outline of how the funds will be expended is required.

ACTA Awards and ACTA Symposium

The lead Health Economist (or a nominated senior member of the trial network or coordinating centre) will be awarded one complimentary ticket to attend and accept the award at the ***ACTA Awards*** on May 20, 2025 and one complimentary registration and an invitation to give a presentation at the ***2025 ACTA Symposium*** (date to be advised) on key lessons learned. Participation in media coverage surrounding the event is expected. Return economy airfares will be provided.

ACTA Clinical Quality Registry Award (*NEW*)

Clinical Quality Registries nominated for the ***ACTA Clinical Quality Registry Award*** will be reviewed by an expert panel convened by the *ACTA Clinical Quality Registries Special Interest Group.* The Clinical Quality Registry must be a current Full or Associate Member of ACTA. The panel will consider nominations based on the following in alignment with the *Australian Framework for National Clinical Quality Registries 2024* and judge the registry that is the best demonstration of the following standards:

- The governance of the registry: including demonstration of exceptional clinical and technical leadership, effective operational arrangements, the software and management systems in place, compliance with legislation and standards including participant identity controls and quality assurance processes
- Data quality: including the scope, scale and interoperability of the data, collection in alignment with core outcome sets and/or METEOR metadata standards (where defined), data linkage capacity and effective data analysis
- Impact: including reporting quality, engagement with relevant stakeholders and end-users of the data; relevant publications and the impact on health outcomes or services (annual reports may be attached as supporting evidence)
- Consumer involvement: inclusion of consumer representatives and/or advisory committees and the collection of PROMs and/or PREMs (where appropriate)

Prize

The Lead Investigator or Chairperson awarded the ***ACTA Clinical Quality Registry Trial Award*** will receive $1,000 to build capacity and capability within the sector through the attendance at a conference, symposium or registry training course. An outline of how the funds will be expended is required.

ACTA Awards and ACTA Symposium

The Lead Investigator, Chairperson (or nominated senior research member of the registry) will be awarded one complimentary ticket to attend and accept the award at the ***ACTA Awards*** on May 20, 2025 to accept the award and one complimentary registration and an invitation to give a presentation at the ***2025 ACTA Symposium*** (date to be advised) on key lessons learned from the registry. Participation in media coverage surrounding the event is expected. Return economy airfares will be provided.

Nominations

Nominations are now open and may be submitted via the online form available on the ACTA website.

The questions for each Award are provided over in Appendix 1.

Nominations close at 5:00pm (AEDT) 24 February 2025.

The ACTA office will contact all Award winners and runners-up by April 24, 2025.

For any queries, please contact ACTA on +61 3 8639 0770 or awards@acta.au

Appendix 1: Form Questions

Nominator details

1.Full name

2.Email address

Award category

3.I wish to nominate a:
Clinical trial
Registry

Trial details

4.Scientific name of the trial

5.Short name or acronym of the trial

6.ACTA member network or group that designed and led the trial

7.Please enter the primary trial results DOI or the URL from which the primary trial results are available

ACTA Trial of the Year Award

8.Do you wish to nominate this trial for the Trial of the Year Award?

9.Chief Investigator full name

10.Chief Investigator email

11.Chief Investigator mobile phone number

12.Please confirm that the trial meets the following eligibility criteria:
Collaboratively developed
Multi-centre
Investigator-driven
Randomised controlled
Primary results published (online or in print) in 2024

13.Did this trial involve any commercial or industry collaboration?

14.Please provide a brief summary, including details of any funding or in-kind support, involvement in the trial development, design, conduct and/or analysis

15.Peer summary
Please provide a brief summary (maximum 600 words) describing the trial and why it warrants recognition as the *ACTA Trial of the Year*. Please address each of the judging criteria below:

1. The trial addressed a critical gap in the evidence or a significant innovation in healthcare delivery
2. The quality of the research design, conduct and analysis were outstanding
3. There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or healthcare delivery.

You may include any web links to relevant publications or websites that support your nomination.

16.Plain English summary
Please provide a brief plain English summary (maximum 400 words) describing the trial and how the results are likely to impact patients and/or the delivery of healthcare. This should be suitable for publication on the ACTA website and in the general media.

ACTA-STInG Excellence in Trial Statistics Award

17.Do you wish to nominate this trial for the ACTA-STInG Excellence in Trial Statistics Award?

18.Please confirm that the **primary results** of this trial were published (online or in print) in 2024

19.Trial Chief Statistician name

20.Trial Chief Statistician email

21.Trial Chief Statistician mobile number

22.Statistical methods summary
Please provide a brief summary (600 words maximum) describing the statistical design and analysis of this trial and why it warrants consideration for the *ACTA STInG Excellence in Trial Statistics Award*. Please address each of the judging criteria below:

1. The statistical aspects of trial design and planning (sample size, randomisation, analytical methods) were of high quality, appropriate for the research question(s), and documented in a publicly accessible statistical analysis plan following good statistical procedures/practice
2. The statistical analyses were executed as planned and, where not, deviations were transparent, of high quality, and executed well following good statistical procedures/practice
3. The reporting and interpretation of the statistical aspects of the trial were appropriate, transparent, and supported by results from pre-specified analyses and/or well-defended departures from planned procedures following good statistical procedures/practice.

23.Supplemental materials
Please provide the web link/s to the **final version** of the supplemental materials listed below.

1. **Trial Protocol** (for platform trials, please include the core protocol and any relevant domain specific appendix)
2. **Statistical Analysis Plan**

If you are unable to provide a web link, please send these files as an email attachment to awards@acta.au with the relevant trial name in the subject line.

ACTA Consumer Involvement Award

24.Do you wish to nominate this trial for the ACTA Consumer Involvement Award?

25.Consumer Investigator / representative name

26.Consumer Investigator / representative email address (alternatively, please provide the name and email of a senior member of the study team)

27.Consumer involvement value
Describe the value to the study of consumer involvement in this clinical trial's activities and why it warrants consideration for the *ACTA Consumer Involvement Award* (max 600 words). Examples may include experiential knowledge, which is often subjective or qualitative. Consider the criteria below:

1. Consumers were significantly involved in protocol development or design activities
2. Consumer involvement provided valuable and exceptional guidance to the proposed conduct of the trial.

You may include any web links to relevant publications or websites that support your nomination.

28.Plain English summary
Please provide a brief summary (400 words maximum) describing the benefit of consumer involvement in the trial, including, where appropriate, the consumer's background and motivation for

involvement. Plain English summaries should be suitable for publication on the ACTA website and in the general media.

ACTA-HEAT Excellence in Trial Based Health Economics Award

29.Do you wish to nominate this trial for the ACTA-HEAT Excellence in Trial Based Health Economics Award?

30.Please confirm that the **health economic analysis of this trial** was published (online or in print) in 2024

31.Lead Health Economist name and health economics group / affiliation / organisation

32.Lead Health Economist email address

33.Lead Health Economist mobile phone number

34.Peer summary
Please describe the health economic analysis and why it warrants consideration for the *ACTA-HEAT Excellence in Trial Based Health Economics Award* (600 words maximum). Consider the criteria below:

1. The health economics aspects of trial design and planning (e.g. collection and valuation of healthcare use data, patient-reported outcomes) were of high quality, and appropriate for the research question(s)
2. The health economics analyses were executed as planned (e.g. as stated in the Health Economics Analysis Plan (HEAP) and, where not, deviations were transparent, of high quality, and well executed following best practices
3. The reporting and interpretation of the health economic analyses and sensitivity analyses were appropriate, transparent, and supported by results
4. The health economics analyses make a significant contribution to trials methodology, or health and social policy, or health impact.

You may include any web links to relevant publications or websites that support your nomination.

35.Plain English summary
Please provide a plain English summary (400 words maximum) describing the health economic analysis and how the results are likely to impact patients and/or the delivery of healthcare. Plain English summaries should be suitable for publication on the ACTA website and in the general media.

36.Supporting documentation
Please provide the web links to the **Health Economics Analysis Plan (HEAP)** and the **economics analysis publication.**

If you are unable to provide web links, please send these files as an email attachment to awards@acta.au with the relevant trial name in the subject line.

ACTA Clinical Quality Registry Award

37.ACTA Member Registry

38.Executive Officer, Chairperson, Lead Investigator or equivalent name

39.Executive Officer, Chairperson, Lead Investigator or equivalent email address

40.Executive Officer, Chairperson, Lead Investigator or equivalent mobile phone number

41.Peer summary
Please provide a peer summary (600 words maximum) describing the registry and why it warrants consideration for the *ACTA Clinical Quality Registry Award*. Consider the criteria below:

1. The governance of the registry: including demonstration of exceptional clinical and technical leadership, effective operational arrangements, the software and management systems in place, compliance with legislation and standards including participant identity controls and quality assurance processes
2. Data quality: including the scope, scale and interoperability of the data, collection in alignment with core outcome sets and/or METEOR metadata standards (where defined), data linkage capacity and effective data analysis
3. Impact: including reporting quality, engagement with relevant stakeholders and end-users of the data; relevant publications and the impact on health outcomes or services (annual reports may be attached as supporting evidence)
4. Consumer involvement: inclusion of consumer representatives and/or advisory committees and the collection of PROMs and/or PREMs (where appropriate)

42.Plain English summary
Please provide a plain English summary (400 words maximum) describing the registry and how the results have, or are likely to, impact patients and/or the delivery of healthcare. Plain English summaries should be suitable for publication on the ACTA website and in the general media.

43.Supporting documentation
Please provide a web link to any relevant supporting documentation, such as annual report/s and/or high-impact publications. A maximum of 3 documents or web pages will be considered by the judging panel.